美国细胞疗法公司传奇生物(LEGN)周三盘中大跌6.46%，尽管公司第三季度财报显示亏损有所收窄。
根据传奇生物公布的2025年第三季度未经审计财务报告，公司净亏损从去年同期的1.253亿美元收窄至3,970万美元。公司主打产品CARVYKTI的净销售额约为5.24亿美元，延续了强劲的环比增长势头。截至2025年9月30日，公司持有现金及现金等价物、定期存款合计约10亿美元。
尽管财务状况有所改善，但市场对传奇生物的反应仍显谨慎。分析人士指出，虽然CARVYKTI销售强劲，但公司整体仍处于亏损状态，且研发费用持续上升。此外，市场可能对公司预期2026年实现整体盈利的目标持观望态度。在生物科技行业整体承压的背景下，投资者似乎更倾向于获利了结，导致股价出现较大幅度下跌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.